Scarica l'app Stockscreener
3.77
0.00%
0.00
Dopo l'orario di chiusura:
3.83
0.06
+1.59%
Precedente Chiudi:
$3.77
Aprire:
$3.825
Volume 24 ore:
902.55K
Relative Volume:
2.39
Capitalizzazione di mercato:
$209.29M
Reddito:
$68.68M
Utile/perdita netta:
$-60.84M
Rapporto P/E:
-2.3563
EPS:
-1.6
Flusso di cassa netto:
$-38.42M
1 W Prestazione:
-27.50%
1M Prestazione:
-44.72%
6M Prestazione:
-39.87%
1 anno Prestazione:
-59.81%
Intervallo 1D:
$3.63
$3.885
Intervallo di 1 settimana:
$3.605
$5.459
Portata 52W:
$3.605
$10.01
Pulmonx Corp Stock (LUNG) Company Profile
Nome
Pulmonx Corp
Settore
Industria
Telefono
650-364-0400
Indirizzo
700 CHESAPEAKE DRIVE, REDWOOD CITY
Confronta LUNG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
3.77 | 209.29M | 68.68M | -60.84M | -38.42M | -1.60 |
|
ABT
Abbott Laboratories
|
132.82 | 223.47B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.93 | 150.72B | 17.55B | 2.03B | 2.37B | 1.37 |
|
SYK
Stryker Corp
|
378.22 | 139.34B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
84.85 | 107.15B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.65 | 44.54B | 5.54B | 4.18B | 259.90M | 7.00 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-10 | Iniziato | D. Boral Capital | Buy |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-06-04 | Iniziato | Lake Street | Buy |
| 2024-02-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | Iniziato | Craig Hallum | Buy |
| 2023-02-27 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2021-12-08 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | Iniziato | Citigroup | Buy |
| 2021-03-25 | Iniziato | Piper Sandler | Neutral |
| 2021-03-10 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-10-26 | Iniziato | BofA Securities | Buy |
| 2020-10-26 | Iniziato | Canaccord Genuity | Buy |
| 2020-10-26 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-10-26 | Iniziato | Stifel | Buy |
| 2020-10-26 | Iniziato | Wells Fargo | Equal Weight |
Mostra tutto
Pulmonx Corp Borsa (LUNG) Ultime notizie
Pulmonx Corp SEC 10-Q Report - TradingView
Pulmonx Corp (NASDAQ: LUNG) Loss Of -10.08% Compared To 52-Week Low; YTD Fall -44.48% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Pulmonx Corp (LUNG) Stock: A Year of Market Movement, Down and Up - investchronicle.com
In the Green: Pulmonx Corp (LUNG) Closes at 3.77, Up/Down -21.95 from Previous Day - DWinneX
Canaccord cuts Pulmonx stock target to $15, maintains Buy rating By Investing.com - Investing.com Nigeria
Pulmonx (LUNG) Price Target Lowered by Canaccord Genuity | LUNG Stock News - GuruFocus
Leading Lung Disease Treatment Pioneer Pulmonx Takes Stage at Bank of America Healthcare Conference - Stock Titan
Pulmonx (LUNG): Analyst Lowers Price Target, Maintains Overweigh - GuruFocus
Pulmonx (LUNG) Maintains "Buy" Rating with Stable Price Target | - GuruFocus
Canaccord cuts Pulmonx stock target to $15, maintains Buy rating - Investing.com
Pulmonx (LUNG) Receives Target Price Adjustment from Canaccord | - GuruFocus
Pulmonx (LUNG) Target Price Adjusted by Piper Sandler Analyst | - GuruFocus
Pulmonx Corp (LUNG) Q1 2025 Earnings Call Highlights: Strong International Growth Amid Domestic ... - Yahoo
BlackRock, Inc. Reduces Stake in Pulmonx Corp: Analyzing the Imp - GuruFocus
Earnings call transcript: Pulmonx beats EPS forecast despite revenue miss in Q1 2025 - Investing.com Nigeria
Pulmonx Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Pulmonx earnings beat by $0.03, revenue topped estimates - Investing.com
Pulmonx (LUNG) Reaffirms 2025 Revenue and Expense Projections | - GuruFocus
LUNG Reports Strong Q1 Revenue, Surpasses Expectations | LUNG St - GuruFocus
Pulmonx Corp (LUNG) Q1 2025 Earnings: EPS Loss of $0.36 Beats Es - GuruFocus
Pulmonx Co. (NASDAQ:LUNG) Shares Purchased by Renaissance Technologies LLC - Defense World
Geode Capital Management LLC Purchases 9,454 Shares of Pulmonx Co. (NASDAQ:LUNG) - Defense World
Pulmonx Co. (NASDAQ:LUNG) Shares Sold by Russell Investments Group Ltd. - Defense World
Pulmonx Co. (NASDAQ:LUNG) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Pulmonx stock plunges to 52-week low of $5.38 amid market challenges - Investing.com Nigeria
Vanguard Group Inc. Grows Stock Holdings in Pulmonx Co. (NASDAQ:LUNG) - Defense World
Pulmonx stock plunges to 52-week low, hitting 4.71 USD By Investing.com - Investing.com Canada
Pulmonx stock plunges to 52-week low, hitting 4.71 USD - Investing.com Australia
Leading Lung Treatment Innovator Pulmonx Announces Q1 2025 Earnings Date - Stock Titan
American Century Companies Inc. Grows Stock Position in Pulmonx Co. (NASDAQ:LUNG) - Defense World
151,200 Shares in Pulmonx Co. (NASDAQ:LUNG) Acquired by Norges Bank - Defense World
Pulmonx Corp’s Banking’s 100-Day Moving Average at 6.80: Will the Stock Break Through? - investchronicle.com
Pulmonx stock plunges to 52-week low of $5.38 amid market challenges By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Boosts Holdings in Pulmonx Co. (NASDAQ:LUNG) - Defense World
Pulmonx Co. (NASDAQ:LUNG) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Connor Clark & Lunn Investment Management Ltd. Buys 25,988 Shares of Pulmonx Co. (NASDAQ:LUNG) - Defense World
Insider Sell Alert: French Glendon E. III Sells 20,000 Shares of Pulmonx Corp (LUNG) - GuruFocus
Pulmonx corp director Glendon French sells $157,000 in stock By Investing.com - Investing.com Canada
Pulmonx corp director Glendon French sells $157,000 in stock - Investing.com
Canaccord maintains Buy rating on Pulmonx stock with $16 target By Investing.com - Investing.com Australia
Canaccord maintains Buy rating on Pulmonx stock with $16 target - Investing.com
Boral Capital sets Pulmonx stock Buy rating, $17 target - Investing.com India
Boral Capital sets Pulmonx stock Buy rating, $17 target By Investing.com - Investing.com South Africa
This Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Pulmonx initiated with a Buy at D. Boral Capital - TipRanks
Pulmonx (NASDAQ:LUNG) vs. Spectral Medical (OTCMKTS:EDTXF) Financial Review - The AM Reporter
Reviewing Pulmonx (NASDAQ:LUNG) & Spectral Medical (OTCMKTS:EDTXF) - Defense World
Pulmonx corp’s chief commercial officer sells $41,191 in stock - Investing.com India
Pulmonx corp general counsel sells shares totaling $170,918 - Investing.com India
Pulmonx CFO Mehul Joshi sells $102,414 in stock By Investing.com - Investing.com Australia
Pulmonx Corp CEO Steven Williamson sells $197,699 in stock - Investing.com India
Pulmonx Corp Azioni (LUNG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):